Indian pharma companies go bullish on overseas buys
According to a research report from Jefferies states, the major player among the Indian pharma companies have now entered the phase of global consolidation, and as such are expected to be on the lookout for more overseas buys.As highlighted in the report, Indian players have already done M and A worth $2 billion in 2015. The research also observed the fact that many new companies like Cipla...
Login or Register to read the full article
According to a research report from Jefferies states, the major player among the Indian pharma companies have now entered the phase of global consolidation, and as such are expected to be on the lookout for more overseas buys.
As highlighted in the report, Indian players have already done M and A worth $2 billion in 2015. The research also observed the fact that many new companies like Cipla and Lupin have recently joined the acquisition bandwagon-announcing large US acquistions.
In the calendar year 2015 there has been mergers and acquisitions (M&A) worth $110 billion which is on track to exceed last year's record M and A of $140 billion, Jefferies said, as reported by IANS.
"With global players like Teva, Mylan increasing their size and relevance, Indian players also need to inorganically grow their portfolios. We expect players like Lupin, Dr Reddy, Torrent to be on the lookout for more acquisitions. Valuations though would be a major concern as price of assets have seen a sharp rise in past couple of years," the Jefferies report stated.
According to the report with the pace of US Food and Drug Administration (USFDA) approvals remaining muted and the global consolidation progressing unabated, M& A by Indian drug companies has increased and the trend is expected to continue.
Though the USFDA approvals have picked up pace it is well below the requirements.
The abbreviated new drug application (ANDA) approvals by USFDA has remained strong for the past five months with 49 ANDAs approved every month against the historical average of 37, the report said.
According to Jefferies, the preference is for Indian companies that are not dependent on US approvals or inorganic drivers for growth.
"Sun Pharma remains our preferred pick among the large caps as we expect earnings to improve going forward led by improvement in Halol supplies and lower Ranbaxy integration expenses. We remain cautious on Lupin as we believe growth will be muted and risks of acquisition at premium valuations are high," the report said.
While the depreciation of Indian currency is positive for the domestic pharma sector, the benefits have been offset by the appreciation of Indian rupee against European currencies, the research report added.
As highlighted in the report, Indian players have already done M and A worth $2 billion in 2015. The research also observed the fact that many new companies like Cipla and Lupin have recently joined the acquisition bandwagon-announcing large US acquistions.
In the calendar year 2015 there has been mergers and acquisitions (M&A) worth $110 billion which is on track to exceed last year's record M and A of $140 billion, Jefferies said, as reported by IANS.
"With global players like Teva, Mylan increasing their size and relevance, Indian players also need to inorganically grow their portfolios. We expect players like Lupin, Dr Reddy, Torrent to be on the lookout for more acquisitions. Valuations though would be a major concern as price of assets have seen a sharp rise in past couple of years," the Jefferies report stated.
According to the report with the pace of US Food and Drug Administration (USFDA) approvals remaining muted and the global consolidation progressing unabated, M& A by Indian drug companies has increased and the trend is expected to continue.
Though the USFDA approvals have picked up pace it is well below the requirements.
The abbreviated new drug application (ANDA) approvals by USFDA has remained strong for the past five months with 49 ANDAs approved every month against the historical average of 37, the report said.
According to Jefferies, the preference is for Indian companies that are not dependent on US approvals or inorganic drivers for growth.
"Sun Pharma remains our preferred pick among the large caps as we expect earnings to improve going forward led by improvement in Halol supplies and lower Ranbaxy integration expenses. We remain cautious on Lupin as we believe growth will be muted and risks of acquisition at premium valuations are high," the report said.
While the depreciation of Indian currency is positive for the domestic pharma sector, the benefits have been offset by the appreciation of Indian rupee against European currencies, the research report added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd